Improvement of Chronic Peyronie's Disease Symptoms After Diabetic Compensation: A Retrospective Study

Published:February 21, 2013DOI:


      To look for a link between compensation of diabetes in patients with uncompensated/undiagnosed diabetes with chronic Peyronie's disease (PD) and improvement of their PD symptoms.


      Thirty-six nonsmoking patients with uncompensated diabetes and PD were studied. The plaque area and pain (ie, PD symptoms) were compared before and after a strict control of hemoglobin A1c and of glycemia at a timeframe of 37 ± 13 weeks. Thirty-two nonsmoking nondiabetic patients with PD who had their PD symptoms assessed twice with a mean time lag of 39 ± 11 weeks were used as controls. The differences in PD symptoms between the 2 assessments were evaluated using the Wilcoxon test. A Spearman rank correlation test was used to identify any correlation between glycemia before diabetic compensation and the percentage of decrease in the size of plaque of patients with diabetes.


      Plaque area and pain diminished in patients with diabetes, coincidentally with diabetes compensation and antidiabetic therapy administration. On the other hand, the controls had their plaque area significantly increased while their pain was not modified. The Spearman tests found a significant correlation between glycemia before diabetic compensation and the percentage of decrease in the size of plaque of patients with diabetes.


      Diabetes compensation and/or antidiabetic therapy improved PD symptoms.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cavallini G.
        • Biagiotti G.
        • Lo Giudice C.
        Association between Peyronie disease and low serum testosterone levels: detection and therapeutic considerations.
        J Androl. 2012; 33: 381-388
        • El-Sakka A.I.
        • Yassin A.A.
        Amelioration of penile fibrosis: myth or reality.
        J Androl. 2010; 31: 324-335
        • Dibenedetti D.B.
        • Nguyen D.
        • Zografos L.
        • et al.
        A population-based study of Peyronie's Disease: prevalence and treatment patterns in the United States.
        Adv Urol. 2011; 2011: 282503
        • Usta M.F.
        • Bivalacqua T.J.
        • Jabren G.W.
        • et al.
        Relationship between the severity of penile curvature and the presence of comorbidities in men with Peyronie's disease.
        J Urol. 2004; 171: 775-779
        • Casabé A.
        • Bechara A.
        • Cheliz G.
        • et al.
        Risk factors of Peyronie's disease. What does our clinical experience show?.
        J Sex Med. 2011; 8: 518-523
        • El-Sakka A.I.
        • Tayeb K.A.
        Peyronie's disease in diabetic patients being screened for erectile dysfunction.
        J Urol. 2005; 174: 1026-1030
        • Tefekli A.
        • Kandirali E.
        • Erol B.
        • et al.
        Peyronie's disease: a silent consequence of diabetes mellitus.
        Asian J Androl. 2006; 8: 75-79
        • World Health Organization (WHO)
        Report of a WHO Consultation. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications.
        in: Alwan A. King H. Part 1: Diagnosis and Classification of Diabetes Mellitus. World Health Organization. Department of Noncommunicable Disease Surveillance, Geneva1999: 1-59
        • Kelâmi A.
        Autophotography in evaluation of functional penile disorders.
        Urology. 1983; 21: 628-629
        • Farrar J.T.
        • Young Jr., J.P.
        • LaMoreaux L.
        • et al.
        Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
        Pain. 2001; 94: 149-158
        • Breyer B.N.
        • Shindel A.W.
        • Huang Y.C.
        • et al.
        Are sonographic characteristics associated with progression to surgery in men with Peyronie's disease?.
        J Urol. 2010; 183: 1484-1488
        • Elhanbly S.
        • Abdel-Gaber S.
        • Fathy H.
        • et al.
        Erectile dysfunction in smokers: a penile dynamic and vascular study.
        J Androl. 2004; 25: 991-995
        • Armitage P.
        Statistical Methods in Medical Research.
        Blackwell Scientific Publishers, Oxford1971
        • Bekos A.
        • Arvaniti M.
        • Hatzimouratidis K.
        • et al.
        The natural history of Peyronie's disease: an ultrasonography-based study.
        Eur Urol. 2008; 53: 644-650
        • Mulhall J.P.
        • Schiff J.
        • Guhring P.
        An analysis of the natural history of Peyronie's disease.
        J Urol. 2006; 175 ([discussion: 2118]): 2115-2118
        • Kadioglu A.
        • Sanli O.
        • Akman T.
        • et al.
        Factors affecting the degree of penile deformity in Peyronie disease: an analysis of 1001 patients.
        J Androl. 2011; 32: 502-508
        • Sikka A.
        • Kaur M.
        • Agarwal C.
        • et al.
        Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation.
        Cell Cycle. 2012; 11: 1374-1382
        • Szardening-Kirchner C.
        • Konrad L.
        • Hauck E.W.
        • et al.
        Upregulation of mRNA expression of MCP-1 by TGF-beta1 in fibroblast cells from Peyronie's disease.
        World J Urol. 2009; 27: 123-130
        • Muyshondt C.
        • Faix A.
        • Costa P.
        • et al.
        Prog Urol. 2012; 22 ([Article in French]): 113-119
        • Levine L.A.
        • Greenfield J.M.
        Establishing a standardized evaluation of the man with Peyronie's disease.
        Int J Impot Res. 2003; 15: S103-S112
        • Vernet D.
        • Nolazco G.
        • Cantini L.
        • et al.
        Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for Peyronie disease.
        Biol Reprod. 2005; 73: 1199-1210
        • Lv Z.M.
        • Wang Q.
        • Wan Q.
        • et al.
        The role of the p38 MAPK signaling pathway in high glucose-induced epithelial-mesenchymal transition of cultured human renal tubular epithelial cells.
        PLoS One. 2011; 6: e22806
        • Suzuki H.
        • Uchida K.
        • Nitta K.
        • et al.
        Role of mitogen-activated protein kinase in the regulation of transforming growth factor-beta-induced fibronectin accumulation in cultured renal interstitial fibroblasts.
        Clin Exp Nephrol. 2004; 8: 188-195
        • Cufí S.
        • Vazquez-Martin A.
        • Oliveras-Ferraros C.
        • et al.
        Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis.
        Cell Cycle. 2010; 9: 4461-4468
        • Shi Y.X.
        • Chen Y.
        • Zhu Y.Z.
        • et al.
        Chronic sodium hydrosulfide treatment decreases medial thickening of intramyocardial coronary arterioles, interstitial fibrosis, and ROS production in spontaneously hypertensive rats.
        Am J Physiol Heart Circ Physiol. 2007; 293: H2093-H2100
        • Mega C.
        • de Lemos E.T.
        • Vala H.
        • et al.
        Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).
        Exp Diabetes Res. 2011; 2011: 162092
        • Uslusoy H.S.
        • Nak S.G.
        • Gülten M.
        Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.
        World J Hepatol. 2011; 3: 219-227
        • Kukla M.
        • Mazur W.
        • Bułdak R.J.
        • et al.
        Potential role of leptin, adiponectin and three novel adipokines–visfatin, chemerin and vaspin–in chronic hepatitis.
        Mol Med. 2011; 17: 1397-1410
        • Euser A.M.
        • Zoccali C.
        • Jager K.J.
        • et al.
        Cohort studies: prospective versus retrospective.
        Nephron Clin Pract. 2009; 113: c214-c217
        • Mantel N.
        Avoidance of bias in cohort studies.
        Natl Cancer Inst Monogr. 1985; 67: 169-172